Last reviewed · How we verify
NCT07151963: CIPN
Effects of Prolonged Continuous Theta Burst Stimulation in Chemotherapy-induced Peripheral Neuropathy
NA trial testing prolonged continuous TBS in Breast Cancer Females in 40 participants. Enrolling by invitation.
31 July 2027
Quick facts
| Lead sponsor | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 17 February 2025 |
| Primary completion | 31 July 2027 |
| Estimated completion | 31 July 2027 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- prolonged continuous TBS
- 20 Hz rTMS
Conditions studied
- Breast Cancer Females — all drugs for Breast Cancer Females →
Sponsor
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Who can join
Adults 18 to 80, female only, with Breast Cancer Females. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Laboratory studies have shown that prolonged continuous theta burst stimulation (pcTBS) provides better pain relief than 10 Hz repetitive transcranial magnetic stimulation (rTMS), with a shorter stimulation time, making it more practical for clinical use. Chemotherapy-induced peripheral neuropathy often causes neuropathic pain in cancer patients. The aims of this study are: 1. To compare the effects of pcTBS and 20 Hz rTMS on chemotherapy-induced peripheral neuropathy; 2. To compare the effects of pcTBS applied to the primary motor cortex versus the dorsolateral prefrontal cortex on neuropathic pain as well as depression and anxiety.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07151963
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Females
Currently open trials in the same condition.
- NCT07256769 — Vitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis · recruiting
- NCT07162675 — Step Count and Treatment Response in Neoadjuvant Breast Cancer · recruiting
- NCT06781762 — Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer · recruiting
- NCT07553702 — Dance Intervention in Breast Cancer Treatment · NA · active not recruiting
- NCT06852833 — One-day Mind Programme for Women With Breast Cancer · NA · active not recruiting
Other Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation trials
Trials by the same sponsor.
- NCT07357142 — Jing Si Herbal Tea as Adjuvant Treatment in Patients With Chronic Pelvic Pain Syndrome · NA · not yet recruiting
- NCT07310797 — Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion · Phase 4 · not yet recruiting
- NCT07472803 — Longitudinal Body Composition Assessment in Breast Cancer Patients · recruiting
- NCT06428942 — Low-potassium Content Vegetables in Chronic Kidney Disease · NA · recruiting
- NCT07096180 — Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07151963 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
- Last refreshed: 11 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07151963.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing